reSET-O, the first PDT to receive Breakthrough Designation and authorized by FDA in December 2018, is an 84-day Prescription Digital Therapeutic (PDT) for Opioid Use Disorder (OUD) intended to increase retention of patients in outpatient treatment by providing cognitive behavioral therapy (CBT), as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician.

Pear Therapeutics, Inc. is a venture-backed digital health company focused on the development of digital therapies and drug/software combinations to treat diseases with high unmet medical need.  PEAR's patented, clinically validated approach is designed to provide enhanced outcomes for patients, actionable data for clinicians, and cost-effective solutions for payers.

https://www.neuroflow.com/integrated-care/

NeuroFlow’s population wide approach to BH support opens up access to care across the spectrum of severity, offering immediate support digitally and de-stressing the system so PCPs feel supported and BH resources are appropriately allocated. 

For systems that already have a (non-CoCM) integrated care program, NF can improve the efficiency and scale of the existing program through better patient ID methods and caseload management tools including risk stratification and clinical decision support. 

For those that don’t have an existing program, NF is an expert partner in guiding toward a sustainable integrated program that produces strong clinical and financial outcomes

NeuroFlow provides the technology infrastructure that leading healthcare organizations need to deliver effective and scalable integrated programs that improve access to behavioral healthcare and lower costs. Powered by proof and clinical expertise, NeuroFlow’s next generation software enables programs to bridge the gap between physical and mental health with proven solutions for psychiatric collaborative care, suicide prevention, and more. To learn more, visit http://www.neuroflow.com

For individuals with substance use disorder (SUD), reSET® is the first FDA-authorized prescription digital therapeutic that’s proven to increase abstinence and treatment retention. Patients download the reSET app to their smartphone for secure, discreet, convenient access to therapy, interactive learning, and support.